{
    "nct_id": "NCT03292406",
    "official_title": "A Randomized, Double-blind, Multi-centre, Placebo-controlled, Parallel-arm Phase 2 Trial to Assess Safety, Efficacy and Pharmacokinetics of CD11301 0.03% and 0.06% Gel in the Treatment of Cutaneous T-Cell Lymphoma (CTCL), Stages IA, IB and IIA",
    "inclusion_criteria": "* Clinical Diagnosis of CTCL stage IA, IB, or IIA with biopsy within last 3 months\n* Have BSA involvement corresponding to stages IA, IB or IIA CTCL with at least 3 distinct lesions\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* CTCL that is stage IIB or great or stage IIA with stage N2 with >5% circulating Sezary cells or CD8+ or large cell transformation or Progressive CTCL\n* History of autoimmune disease\n* Laboratory test values at screening outside of the normal range and judged clinically significant by the investigator\n* Current participation in another clinical trial of a drug or device or past participation within 4 weeks before Baseline or participant is in exclusion period from a previous clinical trial",
    "miscellaneous_criteria": ""
}